DMT-dC(bz) Pharmadite®
SIGMA/C11100P
Synonym: DMT-dC(bz) Phosphoramidite; N-benzoyl-5′-O-[bis(4-methoxyphenyl)phenylmethyl]-2′-deoxycytidine, 3′-[2-cyanoethyl N,N-
Empirical Formula (Hill Notation): C46H52N5O8P
Molecular Weight: 833.91
MDL Number: MFCD00036315
Linear Formula: C46H52N5O8P
Product Type: Chemical
| assay | ≥99.5% (reversed phase HPLC) |
| >99.5% (31P-NMR) | |
| biological source | non-animal source (no BSE/TSE risk) |
| color | white to off-white |
| form | powder or granules |
| impurities | >= 170ppm, none detected (S/N <2.5) |
| ≤0.1% single unspecified Imprity (reversed phase HPLC) | |
| ≤0.3% dC2 (reversed phase HPLC, DMT-dC(bz) cyanoethyl-H-posphonate) | |
| ≤0.3% dC3 (reversed phase HPLC, DMT-dC(bz) phosphoramidate) | |
| ≤0.3% P(III) 100-169ppm (31P-NMR) | |
| ≤0.30 wt. % water content (Karl Fischer) | |
| ≤0.5% P(V) -25-99ppm (31P-NMR) | |
| ≤3.0 wt. % residual solvent content | |
| ≤0.3% dC5 (reversed phase HPLC, O3′-Benzoyl-O5′-DMT-dC(bz |
|
| InChI | 1S/C46H52N5O8P/c1-32(2)51 |
| InChI key | PGTNFMKLGRFZDX-SALLYJDFSA |
| nucleoside profile | base: deoxycytidine base protecting group: benzoyl 2' protecting group: none 5' protecting group: DMT deprotection: standard |
| product line | Proligo Reagents |
| Quality Level | 300  |
| SMILES string | COc1ccc(cc1)C(OC[C@H]2O[C |
| solubility | soluble, clear |
| storage temp. | 2-8°C |
| suitability | conforms to structure for H-NMR |
| conforms to structure for LC-MS | |
| technique(s) | oligo synthesis: suitable |
| type | for DNA synthesis |
| General description: | DMT-dC(bz) Pharmadite® is a Pharmadite® product line that represents a new class of standard protected DNA phosphoramidites designed with highly controlled impurity profiles and exceptional overall purity.Pharmadite phosphoramidites are characterized by their exceptional purity and well-defined impurity profile. In particular, they are essentially free fromcontaminants that interfere in coupling reactions, such as other nucleosidic or non-nucleosidic phosphoramidites (P(III)-contaminants). All remainingimpurities in Pharmadite phosphopramidites, if present, are identified, characterized, and quantified. The impact of any such defined impurities on the synthesis of oligonucleotides is well understood and has been shown to be insignificant. |
| Legal Information: | Pharmadite is a registered trademark of Merck KGaA, Darmstadt, Germany |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 1 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥99.5% (reversed phase HPLC); >99.5% (31P-NMR) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |